Cyclosporine A: Good response for patients affected by autoimmune disorders and HCV infection?

European Review for Medical and Pharmacological Sciences

Volumn 13, Issue SUPPL. 1, 2009, Pages 63-69

  Manna, Raffaele ^a   Verrecchia, E ^a   Fonnesu, C ^a   Giovinale, M ^a   De Socio, G ^a   Curigliano, V ^a   Cerquaglia, C ^a   Soriano, A ^a   Granata, M ^b   Migliore, A ^b   Massafra, U ^b   Gasbarrini, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Department of Rheumatology ^*  (Italy)

Author keywords

Autoantibodies; Autoimmune disorders; Cyclosporine; HCV infection; Interferon

Indexed keywords

AMINOTRANSFERASE; CYCLOSPORIN A; PREDNISONE; VIRUS RNA;

AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCURRENT INFECTION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FUNCTION TEST; MALE; MYASTHENIA GRAVIS; PSORIATIC ARTHRITIS; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; VIRUS GENE; VIRUS LOAD;

AGED; AUTOIMMUNE DISEASES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PILOT PROJECTS; PREDNISONE; RNA, MESSENGER; RNA, VIRAL; VIRAL LOAD;

EID: 65349086124     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. EL-FARRESH MA, ALY HH, WATASHI K, HIJIKATA M, EGAWA H, SHIMOTOHNO K. In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by Cyclosporin. Microbiol Immunol 2007; 5: 127-133.
2. GALEAZZI M, BELLISAI F, MANGANELLI S, MOROZZI G, SEBASTIANI GD. Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients. Autoimmun Review 2006; 5: 493-498.
3. KESSEL A, TOUBI E. Chronic HCV-related autoimmunity: A consequence of viral persistence and lymphotropism. Curr Med Chem 2007; 14: 547-554.
4. GHONAIM M, AL-GHAMDI A, EL-BANA H, BAKR A, GHONEIM E, EL-EDEL R, HASSONA M, SHOEIB S, ALLAM H. Autoantibodies in chronic liver disease. Egypt J Immunol 2005; 12: 101-111.
5. GALEAZZI M, BELLISAI F, GIANNITTI C, MANGANELLI S, MOROZZI G, SEBASTIANI GD. Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann N Y Acad Sci 2007; 1110: 544-549.
6. BELLISAI F, GIANNITTI C, DONVITO A, GALEAZZI M. Combination therapy with cyclosporine A and anti-TNF-α agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 2007; 26: 1127-1129.
7. PALAZZI C, OLIVIERI I, CACCIATORE P, PENNESE E, D'AMICO E. Management of hepatitis C virus-related arthritis. Expert Opin Pharmacother 2005; 6: 27-34.
8. LINARDAKI G, KATSAROU O, IOANNIDOU P, KARAFOULIDOU A, BOKI K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007; 34: 1353-1355.
9. HALFON P, LEVY M, SAN MARCO M, GEROLAMI V, KHIRI H, BOURLIERE M, FERYN JM, GASTAUT JL, POUGET J, CARTOUZOU G. Myasthenia gravis and hepatitis C virus infection. J Viral Hepat 1996; 3: 329-332.
10. LORMEAU C, FALGARONE G, ROULOT D, BOISSIER MC. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine 2006; 73: 633-638.
11. BELLISAI F, GIANNITTI C, DONVITO A, GALEAZZI M. Combination therapy with cyclosporine A and anti-TNF-α agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 2007; 26: 1127-1129.
12. HENRY SD, METSELAAR HJ, VAN DUCK J, TILANUS HW, VAN DER LAAN WLJ. Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann NY Acad Sci 2007; 1110: 439-447.
13. ROBIDA JM, NELSON HB, LIU Z, TANG H. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol 2007; 81: 5829-5840.
14. NEYES J. Selective inhibitors of hepatitis C virus replication. Antiviral Res 2006; 71 363-371.
15. MILLER JL, ERICSON SG. Cyclosporin a and tacrolimus (FK506) differentially alter T-cell receptor expression in vivo. Immunopharmacol Immunotoxicol 2007; 29: 105-118.
16. HENRY SD, METSELAAR JH, LONSDALE RCB, KOK A, BAAGMANS BL, TILANUS HW, VAN DER LAAN UW. Mycophenolic acid inhibits Hepatitis C Virus replication and acts in synergy with Cyclosporin A and Interferon. Gastroenterology 2006; 131: 1452-1462.
17. TERAOKA S, MISHIRO S, EBIHARA K, SANAKA T, YAMAGUSHI Y, NAKAJIMA I. Effect of cyclosporine on proliferation of non A, non B hepatitis virus. Transplant Proc 20; 1988 (S3): 868-876.
18. FERNANDES F, POOLE DS, HOOVER S, MIDDLETON R, ANDREI AC, GERSTNER J, STRIKER R. Sensitivity of hepatitis C virus to Cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology 2007; 46: 1026-1033.
19. SIMMONDS P, HOLMES EC, CHA TA, CHAN SW, MCOMISH F, IRVINE B. Classification of hepattis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the N5 region. J Gen Virol 1993; 74: 2391-2399.
20. FAGIUOLI S, BRUNI F, BRAVI M, CANDUSSO M, GAFFURI G, COLLEDAN M, TORRE G. Cyclosporin in steroid-resistant autoimmune hepatitis and HCV-related liver diseases. Dig Liver Dis 2007; 39(Suppl. 3): S379-S385.
21. MCHUTCHINSON JG, GORDON SC, SCHIFF ER, SHIFFMAN ML, LEE WM, RUSTGI VK, GOODMAN ZD, LING MH, CORT S, ALBRECHT JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. International Therapy Group. N Engl J Med 1998; 339: 1493-1499.
22. SEKIYAMA K, YOSHIBA M, INOUE K. In: Fourth International Symposium on Hepatitis C and Related Virus. Kyoto, Japan, 1997.
23. NAKAGAWA M, SAKAMOTO N, ENOMOTO N, TANABE Y, KANAZAWA N, KOYAMA T, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313: 42-47.
24. WATASHI K, HUIKATA M, HOSAKA M, YAMAJI M, SHIMOTOHNO K. Cyclosporin A suppresses replication of hepatitis C virus in cultured hepatocytes. Hepatology 2003; 38: 1282-1288.
25. INOUE K, SEKIYAMA K, YAMADA M, WATANABE T, YASUDA H, YOSHIBA M. Combined interferon a2b and cyclosporin A in the treatment of chronic hepatitis C: Controlled trial. J Gastroenterol 2003; 38: 567-572.
26. GHOBRIAL RM, COLQUHOUN S, ROSEN H, HOLLIS P, PONTHIEUX S, PAKRASI A, FARMER DG, MARKMAN JF, MARKOWITZ J, DRAZAN K, YERSIZ H, SINGER J, STRIBLING R, ARNOUT W, HOLT CD, GOSS J, IMAGAWA D, SEU P, GOLDSTEIN LI, SHACKLETON CR, MARTIN P, BUSUTTIL RW. Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. Transplant Proc 1998; 30: 1470-1471.
27. LEVY G, VILLAMIL F, SAMUEL D, SANJUAN F, GRAZI GL, WU Y, MAROTTA P, BOILLOT O, MUEHLBACHER F, KLINTMALM G; LIS2T STUDY GROUP. Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with CO monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632-1638.
28. POLLARD S. Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient. Liver Transplant 2004; 24: 402-406.
29. SEBASTIANI GD, BELLISAI F, CAUDAI C, ROTTOLI P, VALENSIN PE, PIPPI L, MOROZZI G, PORCIELLO G, DONVITO A, BILENCHI R, GIANNINI F, GALEAZZI M. Association of extrahepatic manifestations with HLA class II alleles and with virus genotype in HCV infected patients. J Biol Regul Homeost Agents 2005; 19: 17-22.
30. MIURA H, ITOH Y, MATSUMOTO Y, TANI M, TANABE N, ISONOKAMI M, KURACHI K, KOZUKA T. Long-term administration of cyclosporin A to HCV-antibody-positive patients with dermatologic diseases. Int J Dermatol 1999; 38: 310-314.
31. GALEAZZI M, BELLISAI F, SEBASTIANI GD, GIANNITTI C, GARCIA GONZALES E. Utilizzo della ciclosporina in pazienti HCV positivi. Reumatismo 2005; 57: 122-124.
32. PETERSON JR, HSU FC, SIMKIN PA, WENER MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 1078-1082.
33. DAVIS GL, CZAJA AJ, LUDWIG J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1984; 87: 1222-1227.
34. MALEKZADEH R, NASSERI-MOGHADDAM S, KAVIANI M-J, TAHERI H, KAMALIAN N, SOTOUDEH M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46: 1321-1327.
35. FERNANDES FN, REDEKER AG, VIERLING JM, VILLAMIL FG, FONG T-L. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94: 241-248.
36. SHERMAN KE, NARKEWICZ M, PINTO PC. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J Hepatol 1994; 21: 1040-1047.
37. ALVAREZ F, CIOCCA M, CAÑERO-VELASCO C, RAMONET M, DE DAVILA MT, CUARTEROLO M, GONZALEZ T, JARAVEGA P, CAMARENA C, BROCHU P, DRUT R, ALVAREZ E. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999; 30: 222-227.
38. DEBRAY D, MAGGIORE G, GIRARDET JP, MALLER E, BERNARD O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999; 135: 111-114.
39. CUARTEROLO M, CIOCCA M, VELASCO CC, RAMONET M, GONZÁLEZ T, LÓPEZ S, GARSD A, ALVAREZ F. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006; 43: 635-639.